- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Neurogene Inc (NGNE)
Neurogene Inc stock price live, this page displays NASDAQ NGNE stock exchange data. View the NGNE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Neurogene Inc real time stock price chart below.
What Is the Neurogene Inc Stock Price Today?
The Neurogene Inc stock price today is 26.870.
What Is the Stock Symbol for Neurogene Inc?
The stock symbol for Neurogene Inc is "NGNE."
What Stock Exchange Does Neurogene Inc Trade On?
Neurogene Inc is listed and trades on the NASDAQ stock exchange.
Is Neurogene Inc a Good Stock to Buy?
Determining whether Neurogene Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NGNE quote. (ISIN: US64135M1053)
What Is the Neurogene Inc Stock Price Today?
The Neurogene Inc stock price today is 26.870.
What Is the Stock Symbol for Neurogene Inc?
The stock symbol for Neurogene Inc is "NGNE."
What Stock Exchange Does Neurogene Inc Trade On?
Neurogene Inc is listed and trades on the NASDAQ stock exchange.
Is Neurogene Inc a Good Stock to Buy?
Determining whether Neurogene Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NGNE quote. (ISIN: US64135M1053)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
26.780
27.772
52 wk Range
14.650
37.266
NGNE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
26.78027.772
52 wk Range
14.65037.266
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NGNE Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
80.000
Upside
+197.73%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Aquinox Pha receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Aquinox Pha receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K Neurogene Inc For: 20 April
- Investing.com
- Aquinox Pha receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 144 Neurogene Inc. For: 6 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 80.000
(+197.73% Upside)
Neurogene Inc SWOT Analysis
Gene Therapy Promise | Neurogene's NGN-401 shows potential in treating Rett syndrome, a rare neurological disorder, with encouraging safety data and functional activity in preclinical studies |
Market Opportunity | Rett syndrome treatment market estimated at $2.5 billion, with Neurogene's NGN-401 positioned for potential 60% market share in a projected duopoly |
Financial Landscape | Despite negative EPS forecasts through 2025, Neurogene maintains a healthy cash position. Analysts set a $65 price target, reflecting confidence in future growth |
EXACT Platform Edge | Explore Neurogene's EXACT technology, a self-regulatory platform with potential to expand gene therapy applications beyond Rett syndrome to other genetic disorders |
Earnings
Latest Release
May 12, 2026
EPS / Forecast
-1.39 / -1.27
Revenue / Forecast
-- / --
Compare NGNE to Peers and Sector
Metrics to compare | NGNE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNGNEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.3x | −3.4x | −0.5x | |
PEG Ratio | 0.91 | −0.08 | 0.00 | |
Price/Book | 1.8x | 2.4x | 2.6x | |
Price / LTM Sales | - | 11.5x | 3.1x | |
Upside (Analyst Target) | 157.6% | 57.1% | 54.9% | |
Fair Value Upside | Unlock | 1.2% | 7.1% | Unlock |
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Neurogene (NGNE) Stock Price Today?
The Neurogene stock price today is 26.870 USD.
What Stock Exchange Does Neurogene Trade On?
Neurogene is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Neurogene?
The stock symbol for Neurogene is "NGNE."
What Is the Neurogene Market Cap?
As of today, Neurogene market cap is 424.600M USD.
What Is Neurogene's Earnings Per Share (TTM)?
The Neurogene EPS (TTM) is -4.555.
From a Technical Analysis Perspective, Is NGNE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Neurogene Stock Split?
Neurogene has split 2 times.
How Many Employees Does Neurogene Have?
Neurogene has 131 employees.
What is the current trading status of Neurogene (NGNE)?
As of May 28, 2026, Neurogene (NGNE) is trading at a price of 26.870 USD, with a previous close of 26.870 USD. The stock has fluctuated within a day range of 26.780 USD to 27.772 USD, while its 52-week range spans from 14.650 USD to 37.266 USD.
What Is Neurogene (NGNE) Price Target According to Analysts?
The average 12-month price target for Neurogene is 80.000 USD, with a high estimate of 180 USD and a low estimate of 46 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +197.73% Upside potential.
What Is the NGNE After Hours Price?
NGNE's last after hours stock price is 27.630 USD, the stock has decreased by 0.760, or 2.830%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.